Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARS1 | P49591 | 3/20 | 1.00 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.83 |
| ▸ | TARS1 | P26639 | 2/20 | 0.80 |
| ▸ | MARS1 | P56192 | 1/20 | 0.80 |
| ▸ | IARS1 | P41252 | 1/20 | 0.77 |
| ▸ | RARS1 | P54136 | 1/20 | 0.76 |
| ▸ | HARS1 | P12081 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067959 | 1.00 | SARS1 (1.00) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL3187637 | 0.93 | SARS1 (0.87) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL21068060 | 0.93 | SARS1 (0.87) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL3187665 | 0.93 | SARS1 (0.87) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL178823 | 0.92 | SARS1 (0.85) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL30270578 | 0.92 | SARS1 (0.85) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL178824 | 0.92 | SARS1 (0.85) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL13773209 | 0.91 | MARS1 (0.84) | SARS1LARS1TARS1MARS1IARS1 | |
| Leusa SCHEMBL29562511 | 0.91 | LARS1 (1.00) | SARS1LARS1TARS1MARS1IARS1 | |
| SCHEMBL13773211 | 0.91 | MARS1 (0.84) | SARS1LARS1TARS1MARS1IARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582466-B2 | Ablation assembly to treat target regions of tissue in organs | ARGÁ MEDTECH SA (CH) | 2026-03-24 | — | — | US | disclosed |
| US-12564722-B2 | System and method for synchronizing energy delivery to the cardiac rhythm | ANGIODYNAMICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12562230-B2 | Memory device with high content density and encoding method thereof | MACRONIX INTERNATIONAL CO., LTD. (TW) | 2026-02-24 | — | — | US | disclosed |
| EP-4688866-A1 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | Kisoji Biotechnology Inc. (CA) | 2026-02-11 | — | — | EP | disclosed |
| US-12508423-B2 | Device for tissue electrotransfer using a microelectrode | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4161418-B1 | ABLATION EQUIPMENT TO TREAT TARGET REGIONS OF TISSUE IN ORGANS | ARGA MEDTECH SA (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250177741-A1 | FOURIER ANALYSIS SPECTROSCOPY FOR MONITORING TISSUE IMPEDANCE CHANGES AND TREATMENT OUTCOME DURING ELECTROPORATION-BASED-THERAPIES | ANGIODYNAMICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250152230-A1 | IMMUNOTHERAPEUTIC METHODS USING ELECTROPORATION | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-12290688-B1 | System for neurostimulation signal reconstruction | JOHN MICHAEL SASHA (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4540221-A2 | A MULTIFUNCTIONAL BIOADHESIVE DESIGNED WITH CHEMICAL FUNCTIONALITY INDUCED SUTURED BIOLOGICAL BUILDING BLOCKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-23 | — | — | EP | disclosed |
| US-11266839-B1 | Neurostimulation using partial signal combinations | JOHN MICHAEL SASHA (US) | 2022-03-08 | — | — | US | disclosed |
| US-11253705-B1 | Systems and methods for improved spinal cord stimulation | JOHN MICHAEL SASHA (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114057799-A | Organic electroluminescent material and device | 环球展览公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564722-B2 | System and method for synchronizing energy delivery to the cardiac rhythm | RYR2, ATP2A1, ATP2A2 | SARS1 4034/4885LARS1 3657/4885TARS1 2429/4885 |
| US-12582466-B2 | Ablation assembly to treat target regions of tissue in organs | ZYX, XBP1, PFKL | SARS1 1611/4885LARS1 1243/4885TARS1 92/4885 |
| US-12562230-B2 | Memory device with high content density and encoding method thereof | NCS1, HCN1, HCN2 | SARS1 2841/4885LARS1 3961/4885TARS1 3473/4885 |
| US-12508423-B2 | Device for tissue electrotransfer using a microelectrode | CUTA, EPCAM, CD69 | SARS1 346/4885LARS1 996/4885TARS1 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.